Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jenn W. Sellers
Observed name:
Jenn Sellers
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Food and Drug Administration
ORCID:
0000-0002-6383-3494
Observed ORCID:
0000-0002-6383-3494
OpenAlex ID:
A5003065611
The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine
2014
·
Jing Zhang
, Mitchell V. Mathis
, et al.
·
The Journal of Clinical Psychiatry
·
41
Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase
2011
·
Zhen Shi
, Jenn Sellers
, et al.
·
Proteins Structure Function and Bioinformatics
·
35
Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
2022
·
Jenn W. Sellers
, Camelia M. Mihaescu
, et al.
·
Therapeutic Innovation & Regulatory Science
·
21
PDF
Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
2025
·
Cheryl Grandinetti
, Mandy Budwal‐Jagait
, et al.
·
Clinical Pharmacology & Therapeutics
·
8
Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency
2022
·
Kassa Ayalew
, Yang-Min Ning
, et al.
·
Therapeutic Innovation & Regulatory Science
·
6
PDF
A 7-Year Analysis of the U.S. FDA Good Clinical Practice Inspection Outcomes for Marketing Applications
2025
·
Courtney McGuire
, Jenn W. Sellers
, et al.
·
Therapeutic Innovation & Regulatory Science
·
5
PDF
The United States Food and Drug Administration’s Innovative Alternative Tools to Evaluate Good Clinical Practice During the COVID-19 Public Health Emergency
2022
·
Kassa Ayalew
, Jenn Sellers
, et al.
·
Journal of the Society for Clinical Data Management
·
5
PDF
Analyses of U.S. FDA GCP Assessments and Recommendations for Marketing Applications, 2015–2024
2026
·
Courtney McGuire
, Michelle Foringer
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
Lessons and Insights from a Case Study on Clinical Trial Fraud
2026
·
Courtney McGuire
, Jenn W. Sellers
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
2022
·
Jenn W. Sellers
, Camelia M. Mihaescu
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
PDF
Geographic Distribution and Scope of U.S. FDA Good Clinical Practice (GCP) Inspections for Marketing Applications: A Six-Year Update (FY2019-2024)
2026
·
Courtney Stritar McGuire
, Jenn Sellers
, et al.
·
Journal of the Society for Clinical Data Management
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
2022
·
Jenn W. Sellers
, Camelia M. Mihaescu
, et al.
·
Therapeutic Innovation & Regulatory Science
PDF
Show more works
View as search
Works count:
12
Citation count:
124
H-index:
5
I10-index:
3
Year
Topic
Type